Halozyme Therapeutics Inc Cash Flow Reinvestment Rate
Halozyme Therapeutics Inc cash flow reinvestment rate. Halozyme Therapeutics Inc (HALO) has a Cash Flow Reinvestment Rate of 1.15x as of September 2025, reinvesting $204.64 Million (capex $3.03 Million plus investments $201.61 Million) from operating cash flow of $178.60 Million. See financial flexibility index of Halozyme Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Halozyme Therapeutics Inc (2006–2024)
Cash flow reinvestment rate of Halozyme Therapeutics Inc from 2006 to 2024. Historical reinvestment intensity for Halozyme Therapeutics Inc across 7 annual periods. Explore HALO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Halozyme Therapeutics Inc Cash Flow Reinvestment Rate by Year (2006–2024)
Halozyme Therapeutics Inc cash flow reinvestment rate by year from 2006 to 2024. Year-by-year capital reinvestment analysis for Halozyme Therapeutics Inc. For the full cash flow conversion analysis, see HALO cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.57x | $273.42 Million | $479.06 Million | $10.70 Million | ▲ +97.7% |
| 2023 | 0.29x | $112.20 Million | $388.57 Million | $15.29 Million | ▼ -86.0% |
| 2022 | 2.06x | $495.73 Million | $240.11 Million | $4.81 Million | ▲ +52.2% |
| 2021 | 1.36x | $406.29 Million | $299.44 Million | $1.46 Million | ▼ -8.6% |
| 2020 | 1.48x | $82.29 Million | $55.45 Million | $2.50 Million | ▲ +20.5% |
| 2017 | 1.23x | $165.08 Million | $134.05 Million | $1.35 Million | ▲ +2289.9% |
| 2006 | 0.05x | $364.80K | $7.08 Million | $364.80K | — |